179 results
Page 2 of 9
8-K
EX-99.1
eg9d3oezsvflyze6r
10 Jan 22
Results of Operations and Financial Condition
7:04am
8-K
lts1vj
22 Nov 21
Entry into a Material Definitive Agreement
7:03am
424B5
vxbrasari sytjtfs8d
9 Aug 21
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.1
udoq40e 3ec5i9qx472
5 Aug 21
BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
7:06am
8-K
n869dpa4ckyoq90ykn
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
EX-99.1
r1feoe
12 May 21
BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
9:45am
8-K
EX-99.1
exd6omuf4m t3i
6 May 21
BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones
7:09am
8-K
EX-99.1
4oc8o1utnhaag6b
30 Apr 21
Regulation FD Disclosure
10:57am
8-K
EX-99.1
6fjp5xoojew2dl
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
okzmu12 w4
2 Mar 21
Regulation FD Disclosure
7:07am
8-K
EX-99.1
nk5dr5d dg5p
25 Feb 21
Regulation FD Disclosure
4:40pm
8-K
EX-99.1
ek7tboj9yo3l
25 Feb 21
BioCryst Reports Fourth Quarter and Full Year 2020 Financial Results and Upcoming Key Milestones
7:05am
8-K
EX-99.1
ctk9dt 8my
7 Dec 20
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
9:34am
8-K
EX-99.1
hojwkkjgn
4 Dec 20
BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
12:00am